Ectodermal Dysplasias News and Research

RSS

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the enrollment and completed dosing of the first XLHED-affected neonate in a Phase 2 trial of EDI200, the company's novel, proprietary, recombinant protein.

9 Oct 2013

FDA grants Fast Track designation to Edimer’s EDI200 for treatment of XLHED

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for EDI200, the company's novel, proprietary, recombinant protein.

13 Jun 2012

Domain duplication, divergence, and loss events in vertebrate Msx paralogs reveal phylogenomically informed disease markers

The work of Forsyth scientist Peter Jezewski, DDS, Ph.D., has revealed that duplication and diversification of protein regions ('modules') within ancient master control genes is key to the understanding of certain birth disorders.

15 Jan 2009

Ectodermal Dysplasias News and Research

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

FDA grants Fast Track designation to Edimer’s EDI200 for treatment of XLHED

Domain duplication, divergence, and loss events in vertebrate Msx paralogs reveal phylogenomically informed disease markers

Passing on Polycystic Ovary Syndrome: Health risks for male offspring of women with PCOS

Top-Down Proteomics: Bridging the Genotype-to-Phenotype Gap

Bridging the Gap between Academia and Industry: The Power of Collaboration in Life Sciences

Latest News